急性时相血清淀粉样蛋白A对3T3-L1脂肪细胞因子基因、蛋白及相关激酶表达的影响
|
摘要
目的:急性时相血清淀粉样蛋白A(Acute phase serum amyloid protein A, A-SAA)是近年来研究比较多的脂源性细胞因子,其在肥胖(obesity)和2型糖尿病(Type 2 Diabetes Mellitus)等慢性炎症患者血清中表达轻度升高。我们近年研究发现人重组A-SAA能够显著促进ECV304内皮细胞和人脐静脉内皮细胞(HUVECs)IL-6、IL-8 mRNA表达,且呈时间和剂量依赖性,但A-SAA对脂肪细胞炎症因子表达的影响目前尚不明确。本研究旨在探讨急性时相血清淀粉样蛋白A(A-SAA)对3T3-L1脂肪细胞因子白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子-a (Tumor necrosis factor,TNF-α)和脂联素(adiponectin)基因、蛋白及相关激酶表达的影响。
方法:体外培养、诱导分化3T3-L1前脂肪细胞(3T3-L1 preadipocytes),分别用不同浓度的人重组A-SAA(0μg/ml、1μg/ml、10μg/ml、20μg/ml),在不同时间段(0、8h、24h、48h),干预分化成熟的3T3-L1脂肪细胞,用半定量逆转录聚合酶链反应(Reverse transcription Polymerase Chain Reaction,RT-PCR)检测A-SAA对IL-6、TNF-α和adiponectin mRNA表达的影响;用酶联免疫吸附法(Enzyme-linked Immunosorbent Assay,ELISA)检测条件培养基中上述脂肪细胞因子的表达变化;用免疫印迹法(Western Blot)检测A-SAA对相关激酶C-Jun氨基末端激酶( c-jun N-terminal kinase, JNK)和细胞外信号调节激酶(Extracellular signal-regulated kinase ,ERK)蛋白表达的影响。
结果:1、与对照组比较,10μg/ml A-SAA和20μg/ml A-SAA分别干预8h后IL-6 mRNA的表达均显著升高(P<0.05和P<0.01),且20μg/ml A-SAA干预8h组该基因的表达较1μg/ml A-SAA干预8h组也显著升高(P<0.05);与对照组比较,三种浓度的A-SAA分别干预24h后IL-6 mRNA的表达均显著升高(P<0.01),且20μg/ml A-SAA干预24h组该基因的表达较1μg/ml A-SAA干预24h组也显著升高(P<0.01);分别与对照组比较,1μg/ml A-SAA和10μg/ml A-SAA分别干预不同时间后各组IL-6 mRNA表达均显著升高(P<0.05和P<0.01);与对照组比较,20μg/ml A-SAA干预8h组和干预24h组IL-6 mRNA表达显著升高(P<0.01),且20μg/ml A-SAA干预8h组较干预48h组也显著升高(P<0.05);2、与对照组比较,10μg/ml A-SAA干预24h后TNF-a mRNA表达显著升高(P<0.05);3、10μg/ml A-SAA干预24h,使3T3-L1细胞adiponectin mRNA的表达显著下降(P<0.05);4、不同浓度A-SAA干预不同时间后培养基中的TNF-a、IL-6和adiponectin的表达均没有显著变化(P均﹥0.05);5、A-SAA可能激活JNK和ERK。
结论:A-SAA剂量依赖性地促进IL-6 mRNA的表达,10μg/ml A-SAA干预24h使TNF-a和IL-6 mRNA表达显著升高,同时显著降低adiponectin mRNA的表达;A-SAA对条件培养基中脂肪细胞因子蛋白的表达没有影响;A-SAA没有通过促进TNF-a和IL-6表达和(或)降低脂联素表达间接引起胰岛素抵抗,A-SAA可能通过激活MAPK信号通路,参与脂肪细胞的胰岛素抵抗。
Objectives:Acute phase serum amyloid protein A (A-SAA) is one of the frequently studied adipocytokines recently, which present mild increase in obesity and T2DM. Our previous studies showed that human recombinated A-SAA could significantly induce ECV304 endotheliocytes and human umbilical vein endothelial cells,(HUVECs)IL-6、IL-8 mRNA expression in a dose- and time-dependent manner.However,whether A-SAA will effect the expression of inflammatory cytokines in adipocytes is unclear. Our aims are to examine the roles of acute phase serum amyloid protein A in regulating adipocytokines and related kinases expression in 3T3-L1 adipocytes in this study.
Methods:3T3-L1 preadipocytes cultured and differentiated in six-well plates containing high glucose DMEM plus 10% fetal calf serum according to Kolapo M Ajuwon were treated with 3 different concentrations of human recombinated A-SAA(1 ug/ml、10 ug/ml、20 ug/ml) for 3 time periods(8h、24h、48h)after preadipocytes fully differentiated. IL-6、TNF-a and adiponectin mRNA expressions were detected by Reverse transcription Polymerase Chain Reaction(RT-PCR), the concentrations of TNF-a、IL-6 and adiponectin in conditioned media were tested by Enzyme-linked Immunosorbent Assay( ELISA), and the phosphorylated protein expressions of JNK and ERK were detected by Western Blot.
Results:Compared with control group, both 10μg/ml A-SAA and 20μg/ml A-SAA significantly induced the IL-6 mRNA expression respectively after incubated for 8h(P<0.05 and P<0.01)and compared with 1μg/ml A-SAA group, 20μg/ml A-SAA also significantly induced the IL-6 mRNA expression(P<0.05);compared with control group, 3 different concentrations of A-SAA (1 ug/ml、10 ug/ml、20 ug/ml) significantly induced the IL-6 mRNA expression respectively after incubated for 24h(P<0.01)and compared with 1μg/ml A-SAA group, 20μg/ml A-SAA also significantly induced the IL-6 mRNA expression(P<0.01);compared with control group,both 1μg/ml A-SAA and 10μg/ml A-SAA also significantly induced the IL-6 mRNA expression respectively after incubated for different times (8h、24h、48h)(P<0.05 and P<0.01);compared with control group,20μg/ml A-SAA also significantly induced the IL-6 mRNA expression after incubated for 8h and 24h ( P <0.01);compared with control group,the mRNA expression of adiponectin was significantly decreased after stimulated with 10μg/ml A-SAA for 24h(P<0.05), the mRNA expression of TNF-a was significantly increased after treated with 10μg/ml A-SAA for 24h(P<0.05);different concentrations of human recombinated A-SAA with different times did not alter the protein expressions of TNF-a、IL-6 and adiponectin(P﹥0.05)in conditioned media. A-SAA appeared to activate the kinases of JNK and ERK.
Conclusions:A-SAA induced the mRNA expression of IL-6 in a dose-dependent manner, the mRNA expression of adiponectin was significantly decreased after stimulating with 10μg/ml A-SAA for 24h, meanwhile the mRNA expressions of TNF-a and IL-6 was significantly increased when stimulated with 10μg/ml A-SAA for 24h. Therefore,A-SAA did not induce insulin resistance of 3T3-L1 adipocytes through increasing the expression of IL-6 and TNF-a and/or decreasing the expression of adiponectin in this study , A-SAA seemed to participate in the insulin resistance of adioicytes through MAPK pathway.
方法:体外培养、诱导分化3T3-L1前脂肪细胞(3T3-L1 preadipocytes),分别用不同浓度的人重组A-SAA(0μg/ml、1μg/ml、10μg/ml、20μg/ml),在不同时间段(0、8h、24h、48h),干预分化成熟的3T3-L1脂肪细胞,用半定量逆转录聚合酶链反应(Reverse transcription Polymerase Chain Reaction,RT-PCR)检测A-SAA对IL-6、TNF-α和adiponectin mRNA表达的影响;用酶联免疫吸附法(Enzyme-linked Immunosorbent Assay,ELISA)检测条件培养基中上述脂肪细胞因子的表达变化;用免疫印迹法(Western Blot)检测A-SAA对相关激酶C-Jun氨基末端激酶( c-jun N-terminal kinase, JNK)和细胞外信号调节激酶(Extracellular signal-regulated kinase ,ERK)蛋白表达的影响。
结果:1、与对照组比较,10μg/ml A-SAA和20μg/ml A-SAA分别干预8h后IL-6 mRNA的表达均显著升高(P<0.05和P<0.01),且20μg/ml A-SAA干预8h组该基因的表达较1μg/ml A-SAA干预8h组也显著升高(P<0.05);与对照组比较,三种浓度的A-SAA分别干预24h后IL-6 mRNA的表达均显著升高(P<0.01),且20μg/ml A-SAA干预24h组该基因的表达较1μg/ml A-SAA干预24h组也显著升高(P<0.01);分别与对照组比较,1μg/ml A-SAA和10μg/ml A-SAA分别干预不同时间后各组IL-6 mRNA表达均显著升高(P<0.05和P<0.01);与对照组比较,20μg/ml A-SAA干预8h组和干预24h组IL-6 mRNA表达显著升高(P<0.01),且20μg/ml A-SAA干预8h组较干预48h组也显著升高(P<0.05);2、与对照组比较,10μg/ml A-SAA干预24h后TNF-a mRNA表达显著升高(P<0.05);3、10μg/ml A-SAA干预24h,使3T3-L1细胞adiponectin mRNA的表达显著下降(P<0.05);4、不同浓度A-SAA干预不同时间后培养基中的TNF-a、IL-6和adiponectin的表达均没有显著变化(P均﹥0.05);5、A-SAA可能激活JNK和ERK。
结论:A-SAA剂量依赖性地促进IL-6 mRNA的表达,10μg/ml A-SAA干预24h使TNF-a和IL-6 mRNA表达显著升高,同时显著降低adiponectin mRNA的表达;A-SAA对条件培养基中脂肪细胞因子蛋白的表达没有影响;A-SAA没有通过促进TNF-a和IL-6表达和(或)降低脂联素表达间接引起胰岛素抵抗,A-SAA可能通过激活MAPK信号通路,参与脂肪细胞的胰岛素抵抗。
Objectives:Acute phase serum amyloid protein A (A-SAA) is one of the frequently studied adipocytokines recently, which present mild increase in obesity and T2DM. Our previous studies showed that human recombinated A-SAA could significantly induce ECV304 endotheliocytes and human umbilical vein endothelial cells,(HUVECs)IL-6、IL-8 mRNA expression in a dose- and time-dependent manner.However,whether A-SAA will effect the expression of inflammatory cytokines in adipocytes is unclear. Our aims are to examine the roles of acute phase serum amyloid protein A in regulating adipocytokines and related kinases expression in 3T3-L1 adipocytes in this study.
Methods:3T3-L1 preadipocytes cultured and differentiated in six-well plates containing high glucose DMEM plus 10% fetal calf serum according to Kolapo M Ajuwon were treated with 3 different concentrations of human recombinated A-SAA(1 ug/ml、10 ug/ml、20 ug/ml) for 3 time periods(8h、24h、48h)after preadipocytes fully differentiated. IL-6、TNF-a and adiponectin mRNA expressions were detected by Reverse transcription Polymerase Chain Reaction(RT-PCR), the concentrations of TNF-a、IL-6 and adiponectin in conditioned media were tested by Enzyme-linked Immunosorbent Assay( ELISA), and the phosphorylated protein expressions of JNK and ERK were detected by Western Blot.
Results:Compared with control group, both 10μg/ml A-SAA and 20μg/ml A-SAA significantly induced the IL-6 mRNA expression respectively after incubated for 8h(P<0.05 and P<0.01)and compared with 1μg/ml A-SAA group, 20μg/ml A-SAA also significantly induced the IL-6 mRNA expression(P<0.05);compared with control group, 3 different concentrations of A-SAA (1 ug/ml、10 ug/ml、20 ug/ml) significantly induced the IL-6 mRNA expression respectively after incubated for 24h(P<0.01)and compared with 1μg/ml A-SAA group, 20μg/ml A-SAA also significantly induced the IL-6 mRNA expression(P<0.01);compared with control group,both 1μg/ml A-SAA and 10μg/ml A-SAA also significantly induced the IL-6 mRNA expression respectively after incubated for different times (8h、24h、48h)(P<0.05 and P<0.01);compared with control group,20μg/ml A-SAA also significantly induced the IL-6 mRNA expression after incubated for 8h and 24h ( P <0.01);compared with control group,the mRNA expression of adiponectin was significantly decreased after stimulated with 10μg/ml A-SAA for 24h(P<0.05), the mRNA expression of TNF-a was significantly increased after treated with 10μg/ml A-SAA for 24h(P<0.05);different concentrations of human recombinated A-SAA with different times did not alter the protein expressions of TNF-a、IL-6 and adiponectin(P﹥0.05)in conditioned media. A-SAA appeared to activate the kinases of JNK and ERK.
Conclusions:A-SAA induced the mRNA expression of IL-6 in a dose-dependent manner, the mRNA expression of adiponectin was significantly decreased after stimulating with 10μg/ml A-SAA for 24h, meanwhile the mRNA expressions of TNF-a and IL-6 was significantly increased when stimulated with 10μg/ml A-SAA for 24h. Therefore,A-SAA did not induce insulin resistance of 3T3-L1 adipocytes through increasing the expression of IL-6 and TNF-a and/or decreasing the expression of adiponectin in this study , A-SAA seemed to participate in the insulin resistance of adioicytes through MAPK pathway.
引文
[1] Lyon C, Law R, Hsueh W. Adiposity, inflammation, and athero-genesis. Endocrinology, 2003, 144: 2195-2200.
[2] Wozniak SE,Gee LL,Wachtel MS,Frezza EE. Adipose Tissue: The New Endocrine Organ? A Review Article. Dig Dis Sci 2008 Dec 4.
[3] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
[4] Manley PN, Ancsin JB, Kisilevsky R. Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 66: 784-792, 2006.
[5] Sodin-Semrl S, Zigon P, Cucnik S, et al. Serum amyloid A in autoimmune thrombosis. Autoimmun Rev 6:21-7, 2006.
[6] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523, 1999.
[7] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
[8] Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000;7:64-69.
[9] Rong-Ze Yang,Da-Wei Gong. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006 Jun;3(6):e287.
[10] Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46: 389-403, 2005.
[11] Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association ofc-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. Atherosclerosis 156: 451-456, 2001.
[12] Mezaki T, Matsubara T, Hori T, et al. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 44:601-612, 2003.
[13] Mezaki T, Matsubara T, Hori T, et al. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 44:601-612, 2003.
[14] Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166: 387-394, 2003.
[15] Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 48: 81-89, 2003.
[16] Badolato R, Wang JM, Stornello SL, et al. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti-Candida activity. J Leukoc Biol 67: 381-386, 2000.
[17] Rong L. He, Jian Zhou, Richard D. Ye.Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood. 2009 January 8; 113(2): 429–437.
[18] Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells.Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2399-408.
[19] Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature, 2002, 420: 333-336.
[20] Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity2 anddiet2induced insulin resistance with salicylates or targeted disrup tion of Ikkb. Science, 2001, 293: 1673-1677.
[21] Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
[22]李秀钧,邬云红。糖尿病是一种炎症性疾病?中华内分泌代谢杂志,2003,19:251-253.
[23] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
[24] Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000;7:64-69.
[25] Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acutephase reactant for clinical practice. Eur. J. Clin. Invest. 1996;26:427-435.
[26] Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation. 1997;96:2914-2919.
[27] Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983;42:665-667.
[28] Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987;17:460-467.
[29] Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Interaction between serum amyloid A and leukocytes - a possible role in the progression of vascular complications in diabetes. Immunol Lett. 2007;108:160-166.
[30] Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem. 1994;27:469-473.
[31] Lange U, Boss B, Teichmann J, Klor HU, Neeck G. Serum amyloid A--an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000;19:119-122.
[32] Ebeling P, Teppo AM, Koistinen HA, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia. 1999, 42: 1433-1438.
[33] O'Brien KD, Brehm BJ, Seeley RJ, et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C reactive protein independent of dietary macronutrient composition in obese subjects. Journal of Clinical Endocrinology & Metabolism. 2005 Apr;90(4):2244-9.
[34] Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab, 2004, 89:2728-2735.
[35]Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A. 1977;74:4025-4028.
[36] Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 1995;36:1058- 1065.
[37] Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, de Beer FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res. 1999;40:648-653.
[38] Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. U. S. A.1994;91:3186-3190.
[39] Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J. Rheumatol. 1999;26:785-790.
[40] Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, Oppenheim JJ. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 1994;180:203- 209.
[41] Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, Oppenheim JJ, Wang JM. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 1995;155:1184-1190.
[42] Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seventransmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999;189:395-402.
[43] Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405-408.
[44] He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G proteincoupled receptor, FPRL1/LXA4R. Blood. 2003;101:1572-1581.
[45] Cai H, Song C, Endoh I, Goyette J, Jessup W, Freedman SB, McNeil HP, Geczy CL. Serum amyloid A induces monocyte tissue factor. J Immunol. 2007;178:1852-1860.
[46] Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys ResCommun. 2005;330:989- 998.
[47] Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, Remaley AT, Csako G, Thomas F, Eggerman TL, Patterson AP. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005;280:8031-8040.
[48] Anders H, Philipp E. Scherer. Adipose Tissue, Inflammation, and Cardiovascular Disease(J). Circulation Research, 2005;96:939.
[49] Tomohiro Kogaa, Takafumi Torigoshib, Kiyoshi Migitaa, et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Letters 582 (2008) 579–585.
[50] He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood, 2003, 101: 1572-1581.
[51] Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 2005, 11:183-190.
[52] Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity induced insulin resistance. Nat Med, 2005, 11:191-198.
[1]Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788
[2]Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
[3]Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R, Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657-1669
[4] Reaven P (2004) Metabolic syndrome. J Insur Med 36: 132–142.
[5]Yudkin JS (2003) Adipose tissue, insulin action and vascular disease:Inflammatory signals. Int J Obes Relat Metab Disord 27: S25–S28.
[6]Schmidt MI, Duncan BB (2003) Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med 41: 1120–1130.
[7]Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance.Science 259: 87–91.
[8] Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847–850.
[9]Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100: 7265–7270.
[10] Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular diseasein obesity. Nat Med 2: 800–803.
[11] Fain JN, Bahouth SW, Madan AK (2004) TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 28: 616–622.
[12]Arner P. Insulin resistance in type 2 diabetes– role of the adipokines. Curr MoMed 2005; 5: 333-339
[13]Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830
[14] Herbert Tilg , Alexander R Moschen(.2008)Inflammatory Mechanisms in the Regulation of Insulin Resistance. MOL MED 14:222-231.
[15]Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27 Suppl 3: S53-S55
[16]Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-976
[17]Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
[18] Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-145
[19]Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 1999; 274: 6770-6775
[20]Fasshauer M, Klein J, Lossner U, Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha,growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 2003; 35: 147-152
[21] Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factoralpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32: 548-554
[22] Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-455
[23] Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885
[24]Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200
[25] Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45: 828-833
[26]Uy s a l KT , Wi e s b r o c k SM, Ma r i n o MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614
[27]Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzuc chi S, Shoe l son SE, Shulman GI . Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326
[28] Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336
[29] Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatorypathway. Curr Opin Investig Drugs 2005; 6: 979-987
[30]Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y, Hori M. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 10: 1128-1132
[31]Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y, Hori M. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004; 279: 45803-45809
[32]Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005; 54 Suppl 2: S73-S78
[33] Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850
[34]Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 2001; 86: 2281-2288
[35] Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factoralpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777-45784
[36]Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399
[37] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334
[38]Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA,Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 2005; 288: E155-E162
[39]Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167-4170
[40]Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79
[41] Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
[42]Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23: 831-834
[43] Dandona P, Al jada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
[44] Sellar GC, Jordan SA, Bickmore WA, Fantes JA, van Heyningen V, et al.(1994) The human serum amyloid A protein (SAA) superfamily gene cluster: Mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics 19: 221–227.
[45]Kluve-Beckerman B, Drumm ML, Benson MD (1991) Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 10: 651–661.
[46]Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, et al. (1992) Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 267: 3862–3867.
[47] Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454.
[48] Ludger Scheja, Barbara Heese, Heike Zitzer, Mervyn D.Michael, Angela M. Siesky,et al(.2008)Acute-Phase Serum Amyloid A as a Marker of Insulin Resistance inMice. Experimental Diabetes Research Volume 2008 1-11.
[49]Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, et al. (2005) Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48: 519–528.
[50]Sjoholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, et al.(2005) A microarray search for genes predominantly expressed in human omental adipocytes: Adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 90: 2233–2239.
[51]Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, et al. (2001) Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276: 42077–42083.
[52]Rong-Ze Yang, Mi-Jeong Lee, Hong Hu, Toni I. Pollin, Alice S. Ryan, et al.(2006) Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications. PLoS MEDICINE 3:0884-0894.
[53] van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, et al.(2001) Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25: 1759–1766.
[54] Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T (2001) The association of c-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease—Baseline findings of the PAIS project. Atherosclerosis 156: 451–456.
[55] Furlaneto CJ, Campa A (2000) A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 268: 405–408.
[56]Hatanaka E, Furlaneto CJ, Ribeiro FP, Souza GM, Campa A (2004) Serum amyloid A-induced mRNA expression and release of tumor necrosis factoralpha (TNF-alpha) in human neutrophils. Immunol Lett 91: 33–37.
[57] Ribeiro FP, Furlaneto CJ, Hatanaka E, Ribeiro WB, Souza GM, et al. (2003) mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm 12: 173–178.
[58]Thorn CF, Lu ZY, Whitehead AS (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152–158.
[59]He R, Sang H, Ye RD (2003) Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572–1581.
[60]Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183–190.
[61]Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191–198.
[62]Tomohiro Koga, Takafumi Torigoshi, Satoru Motokawa, et al.(2008) Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Letters 582:579–585
[63]Peter Sartipy ,David J. Loskutoff.(2003)Monocyte chemoattractant protein 1 in obesity and insulin resistance.PANS 100:726
[2] Wozniak SE,Gee LL,Wachtel MS,Frezza EE. Adipose Tissue: The New Endocrine Organ? A Review Article. Dig Dis Sci 2008 Dec 4.
[3] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
[4] Manley PN, Ancsin JB, Kisilevsky R. Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 66: 784-792, 2006.
[5] Sodin-Semrl S, Zigon P, Cucnik S, et al. Serum amyloid A in autoimmune thrombosis. Autoimmun Rev 6:21-7, 2006.
[6] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523, 1999.
[7] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
[8] Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000;7:64-69.
[9] Rong-Ze Yang,Da-Wei Gong. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006 Jun;3(6):e287.
[10] Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46: 389-403, 2005.
[11] Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association ofc-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. Atherosclerosis 156: 451-456, 2001.
[12] Mezaki T, Matsubara T, Hori T, et al. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 44:601-612, 2003.
[13] Mezaki T, Matsubara T, Hori T, et al. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 44:601-612, 2003.
[14] Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166: 387-394, 2003.
[15] Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 48: 81-89, 2003.
[16] Badolato R, Wang JM, Stornello SL, et al. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti-Candida activity. J Leukoc Biol 67: 381-386, 2000.
[17] Rong L. He, Jian Zhou, Richard D. Ye.Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood. 2009 January 8; 113(2): 429–437.
[18] Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells.Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2399-408.
[19] Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature, 2002, 420: 333-336.
[20] Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity2 anddiet2induced insulin resistance with salicylates or targeted disrup tion of Ikkb. Science, 2001, 293: 1673-1677.
[21] Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
[22]李秀钧,邬云红。糖尿病是一种炎症性疾病?中华内分泌代谢杂志,2003,19:251-253.
[23] Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
[24] Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 2000;7:64-69.
[25] Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acutephase reactant for clinical practice. Eur. J. Clin. Invest. 1996;26:427-435.
[26] Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation. 1997;96:2914-2919.
[27] Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983;42:665-667.
[28] Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987;17:460-467.
[29] Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Interaction between serum amyloid A and leukocytes - a possible role in the progression of vascular complications in diabetes. Immunol Lett. 2007;108:160-166.
[30] Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K. Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem. 1994;27:469-473.
[31] Lange U, Boss B, Teichmann J, Klor HU, Neeck G. Serum amyloid A--an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000;19:119-122.
[32] Ebeling P, Teppo AM, Koistinen HA, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia. 1999, 42: 1433-1438.
[33] O'Brien KD, Brehm BJ, Seeley RJ, et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C reactive protein independent of dietary macronutrient composition in obese subjects. Journal of Clinical Endocrinology & Metabolism. 2005 Apr;90(4):2244-9.
[34] Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab, 2004, 89:2728-2735.
[35]Benditt EP, Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A. 1977;74:4025-4028.
[36] Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 1995;36:1058- 1065.
[37] Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, de Beer FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res. 1999;40:648-653.
[38] Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. U. S. A.1994;91:3186-3190.
[39] Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J. Rheumatol. 1999;26:785-790.
[40] Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, Oppenheim JJ. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 1994;180:203- 209.
[41] Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, Oppenheim JJ, Wang JM. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 1995;155:1184-1190.
[42] Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM. A seventransmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999;189:395-402.
[43] Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun. 2000;268:405-408.
[44] He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G proteincoupled receptor, FPRL1/LXA4R. Blood. 2003;101:1572-1581.
[45] Cai H, Song C, Endoh I, Goyette J, Jessup W, Freedman SB, McNeil HP, Geczy CL. Serum amyloid A induces monocyte tissue factor. J Immunol. 2007;178:1852-1860.
[46] Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys ResCommun. 2005;330:989- 998.
[47] Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, Remaley AT, Csako G, Thomas F, Eggerman TL, Patterson AP. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005;280:8031-8040.
[48] Anders H, Philipp E. Scherer. Adipose Tissue, Inflammation, and Cardiovascular Disease(J). Circulation Research, 2005;96:939.
[49] Tomohiro Kogaa, Takafumi Torigoshib, Kiyoshi Migitaa, et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Letters 582 (2008) 579–585.
[50] He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood, 2003, 101: 1572-1581.
[51] Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med, 2005, 11:183-190.
[52] Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity induced insulin resistance. Nat Med, 2005, 11:191-198.
[1]Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788
[2]Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
[3]Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R, Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657-1669
[4] Reaven P (2004) Metabolic syndrome. J Insur Med 36: 132–142.
[5]Yudkin JS (2003) Adipose tissue, insulin action and vascular disease:Inflammatory signals. Int J Obes Relat Metab Disord 27: S25–S28.
[6]Schmidt MI, Duncan BB (2003) Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med 41: 1120–1130.
[7]Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance.Science 259: 87–91.
[8] Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847–850.
[9]Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100: 7265–7270.
[10] Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular diseasein obesity. Nat Med 2: 800–803.
[11] Fain JN, Bahouth SW, Madan AK (2004) TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 28: 616–622.
[12]Arner P. Insulin resistance in type 2 diabetes– role of the adipokines. Curr MoMed 2005; 5: 333-339
[13]Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830
[14] Herbert Tilg , Alexander R Moschen(.2008)Inflammatory Mechanisms in the Regulation of Insulin Resistance. MOL MED 14:222-231.
[15]Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27 Suppl 3: S53-S55
[16]Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-976
[17]Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
[18] Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-145
[19]Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 1999; 274: 6770-6775
[20]Fasshauer M, Klein J, Lossner U, Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha,growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 2003; 35: 147-152
[21] Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factoralpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32: 548-554
[22] Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-455
[23] Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885
[24]Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200
[25] Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45: 828-833
[26]Uy s a l KT , Wi e s b r o c k SM, Ma r i n o MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614
[27]Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzuc chi S, Shoe l son SE, Shulman GI . Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326
[28] Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336
[29] Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatorypathway. Curr Opin Investig Drugs 2005; 6: 979-987
[30]Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y, Hori M. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 10: 1128-1132
[31]Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y, Hori M. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004; 279: 45803-45809
[32]Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005; 54 Suppl 2: S73-S78
[33] Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850
[34]Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 2001; 86: 2281-2288
[35] Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factoralpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278: 45777-45784
[36]Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399
[37] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334
[38]Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA,Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 2005; 288: E155-E162
[39]Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167-4170
[40]Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79
[41] Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
[42]Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23: 831-834
[43] Dandona P, Al jada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
[44] Sellar GC, Jordan SA, Bickmore WA, Fantes JA, van Heyningen V, et al.(1994) The human serum amyloid A protein (SAA) superfamily gene cluster: Mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics 19: 221–227.
[45]Kluve-Beckerman B, Drumm ML, Benson MD (1991) Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 10: 651–661.
[46]Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, et al. (1992) Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 267: 3862–3867.
[47] Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454.
[48] Ludger Scheja, Barbara Heese, Heike Zitzer, Mervyn D.Michael, Angela M. Siesky,et al(.2008)Acute-Phase Serum Amyloid A as a Marker of Insulin Resistance inMice. Experimental Diabetes Research Volume 2008 1-11.
[49]Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, et al. (2005) Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48: 519–528.
[50]Sjoholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, et al.(2005) A microarray search for genes predominantly expressed in human omental adipocytes: Adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 90: 2233–2239.
[51]Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, et al. (2001) Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276: 42077–42083.
[52]Rong-Ze Yang, Mi-Jeong Lee, Hong Hu, Toni I. Pollin, Alice S. Ryan, et al.(2006) Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications. PLoS MEDICINE 3:0884-0894.
[53] van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, et al.(2001) Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25: 1759–1766.
[54] Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T (2001) The association of c-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease—Baseline findings of the PAIS project. Atherosclerosis 156: 451–456.
[55] Furlaneto CJ, Campa A (2000) A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 268: 405–408.
[56]Hatanaka E, Furlaneto CJ, Ribeiro FP, Souza GM, Campa A (2004) Serum amyloid A-induced mRNA expression and release of tumor necrosis factoralpha (TNF-alpha) in human neutrophils. Immunol Lett 91: 33–37.
[57] Ribeiro FP, Furlaneto CJ, Hatanaka E, Ribeiro WB, Souza GM, et al. (2003) mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm 12: 173–178.
[58]Thorn CF, Lu ZY, Whitehead AS (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152–158.
[59]He R, Sang H, Ye RD (2003) Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572–1581.
[60]Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183–190.
[61]Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191–198.
[62]Tomohiro Koga, Takafumi Torigoshi, Satoru Motokawa, et al.(2008) Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Letters 582:579–585
[63]Peter Sartipy ,David J. Loskutoff.(2003)Monocyte chemoattractant protein 1 in obesity and insulin resistance.PANS 100:726